In view of the emerging role of PARP-1 as a therapeutic target in CRC and the limitations observed for established PARPi, we aimed to identify PARPi with novel scaffolds and lower toxicity, in order to test their activity in MSI and MSS CRC cell lines without or with DDR defects. This evidence concerns the gene PARP1 and colorectal carcinoma.